Cargando…

Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials

Background: Advanced hormone-receptor positive HER2 negative breast cancer is a common and a very heterogeneous disease. Hormone therapy is the main first line treatment of choice, given alone or in combination with other agents that have shown to improve patient outcomes, Nevertheless, treatment re...

Descripción completa

Detalles Bibliográficos
Autores principales:	El Sayed, Rola, El Jamal, Lara, El Iskandarani, Sarah, Kort, Jeries, Abdel Salam, Mahmoud, Assi, Hazem
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6597942/ https://www.ncbi.nlm.nih.gov/pubmed/31281796 http://dx.doi.org/10.3389/fonc.2019.00510

Ejemplares similares

Preferences for the sequencing of first-line systemic treatments in metastatic hormone receptor-positive, HER2-negative breast cancer
por: Al Mahmasani, Layal, et al.
Publicado: (2023)

Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study
por: López González, Ana, et al.
Publicado: (2022)

Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
por: D’Souza, Anishka, et al.
Publicado: (2018)

Frequent Upregulation Of HER2 Protein In Hormone Receptor-Positive HER2-Negative Breast Cancer After Short-Term Neoadjuvant Endocrine Therapy
por: Chaudhary, Lubna Naaz, et al.
Publicado: (2023)

Thromboembolic Events in Patients with HER2-Negative, Hormone Receptor-Positive, Metastatic Breast Cancer Treated with Ribociclib Combined with Letrozole or Fulvestrant: A Real-World Data
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2022)

Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer—A Literature Review
por: Mata, Danilo Giffoni de Mello Morais, et al.
Publicado: (2022)

Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer
por: Shah, Ami N, et al.
Publicado: (2020)

MET Inhibitors for the Treatment of Gastric Cancer: What’s Their Potential?
por: El Darsa, Haidar, et al.
Publicado: (2020)

Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review
por: Reinert, Tomás, et al.
Publicado: (2017)

Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer
por: Lin, Mingxi, et al.
Publicado: (2020)

2-Hydroxyestradiol Overcomes Mesenchymal Stem Cells-Mediated Platinum Chemoresistance in Ovarian Cancer Cells in an ERK-Independent Fashion
por: Khamaisi, Hazem, et al.
Publicado: (2022)

Pituitary, Gonadal, Thyroid Hormones and Endocrine Disruptors in Pre and Postmenopausal Nigerian Women with ER-, PR- and HER-2-Positive and Negative Breast Cancers
por: Ajayi, Olulope, et al.
Publicado: (2018)

Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis
por: Brandão, Mariana, et al.
Publicado: (2020)

Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial
por: Demir, Atakan, et al.
Publicado: (2020)

Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series
por: Schettini, Francesco, et al.
Publicado: (2020)

Primary Diffuse Large B-cell Lymphoma of the Sigmoid Colon
por: Haddad, Ibrahim, et al.
Publicado: (2019)

Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis
por: Schettini, Francesco, et al.
Publicado: (2021)

Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study
por: Tolaney, Sara M., et al.
Publicado: (2022)

Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer
por: Yuan, Yang, et al.
Publicado: (2023)

Interplay between Epigenetics, Expression of Estrogen Receptor- α, HER2/ERBB2 and Sensitivity of Triple Negative Breast Cancer Cells to Hormonal Therapy
por: Ramadan, Wafaa S, et al.
Publicado: (2018)

Hormonal treatment combined with targeted therapies in endocrine-responsive and HER2-positive metastatic breast cancer
por: Montagna, Emilia, et al.
Publicado: (2019)

CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer
por: Nabieva, Naiba, et al.
Publicado: (2023)

Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer
por: Yu, Ke-Da, et al.
Publicado: (2015)

Neural and Endocrinal Pathobiochemistry of Vitiligo: Comparative Study for a Hypothesized Mechanism
por: Kotb El-Sayed, Mohamed-I., et al.
Publicado: (2018)

Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy
por: Bonechi, Martina, et al.
Publicado: (2018)

First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis
por: Shimoi, Tatsunori, et al.
Publicado: (2020)

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial
por: Adamo, Barbara, et al.
Publicado: (2019)

Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China
por: Yang, Jiao, et al.
Publicado: (2023)

Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
por: Davis, Andrew A., et al.
Publicado: (2023)

Genetic and physiological variation in two strains of Japanese quail
por: Ibrahim, Nashat Saeid, et al.
Publicado: (2021)

Endocrine Disruption: Computational Perspectives on Human Sex Hormone-Binding Globulin and Phthalate Plasticizers
por: Sheikh, Ishfaq A., et al.
Publicado: (2016)

Prognostic role of albumin level in heart failure: A systematic review and meta-analysis
por: El Iskandarani, Mahmoud, et al.
Publicado: (2021)

ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC)
por: Ferrando, Lorenzo, et al.
Publicado: (2023)

Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer
por: Le, Vivian, et al.
Publicado: (2021)

Systematic review of hormone replacement therapy in the infertile man
por: El Meliegy, Amr, et al.
Publicado: (2017)

Chromogranin A‐positive hormone‐negative endocrine cells in pancreas in human pregnancy
por: Moin, Abu Saleh Md, et al.
Publicado: (2021)

Hormone Receptor Positive/HER2 Negative Breast Cancer With Isolated Bladder Metastasis: A Rare Case
por: Khan, Noman Ahmed Jang, et al.
Publicado: (2021)

Immunotherapy in Extensive-Stage Small Cell Lung Cancer
por: El Sayed, Rola, et al.
Publicado: (2021)

Fragmentation of Ventricular Extrasystoles: A Potential New Electrocardiographic Window to Uncover Patients at Risk
por: Shatla, Islam M, et al.
Publicado: (2021)

Overcoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 Inhibitors
por: O’Sullivan, Ciara C
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_fml2ueg0dsghintocm8815rkm2